Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Open-Label Phase III Trial of Pembrolizumab Versus Platinum Based Chemotherapy in 1L Subjects With PD-L1 Strong Metastatic Non-Small Cell Lung Cancer
Brief Summary: This is a study to assess the efficacy and safety of pembrolizumab (MK-3475/SCH 900475) compared to standard of care (SOC) platinum-based chemotherapies in the treatment of participants with previously untreated stage IV, programmed cell death ligand 1 (PD-L1) strong expressing Non-Small Cell Lung Cancer (NSCLC). The primary hypothesis of this study is that participants with PD-L1 strong NSCLC will have a longer Progression Free Survival (PFS), as assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) when treated with pembrolizumab than when treated with SOC platinum-based chemotherapies.

With Amendment 09 (20 December 2017), once participants have achieved the study objective or the study has ended, participants will be discontinued from this study and enrolled in an extension study to continue protocol-defined assessments and treatment.


Options:
A: Arm Label: Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab 200 mg, Drug: Cisplatin, Drug: Carboplatin, Drug: Pemetrexed, Dietary Supplement: Folic acid 350-1000 μg, Dietary Supplement: Vitamin B12 1000 μg, Drug: Dexamethasone 4 mg | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Carboplatin, Drug: Pemetrexed, Dietary Supplement: Folic acid 350-1000 μg, Dietary Supplement: Vitamin B12 1000 μg, Drug: Dexamethasone 4 mg, Drug: Saline solution | Intervention Type: BIOLOGICAL; Name: Pembrolizumab 200 mg; Assigned to Arm(s): Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Control, Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Control, Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Control, Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid 350-1000 μg; Assigned to Arm(s): Control, Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin B12 1000 μg; Assigned to Arm(s): Control, Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed | Intervention Type: DRUG; Name: Dexamethasone 4 mg; Assigned to Arm(s): Control, Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed | Intervention Type: DRUG; Name: Saline solution; Assigned to Arm(s): Control
B: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab | Arm Label: Paclitaxel+Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Pemetrexed | Arm Label: Pemetrexed+Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Pemetrexed | Arm Label: Pemetrexed+Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed, Drug: Cisplatin | Arm Label: Gemcitabine+Carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Gemcitabine | Arm Label: Gemcitabine+Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Gemcitabine | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel+Carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Gemcitabine+Carboplatin, Paclitaxel+Carboplatin, Pemetrexed+Carboplatin | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Paclitaxel+Carboplatin, Pemetrexed+Carboplatin, Pemetrexed+Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Gemcitabine+Cisplatin, Pemetrexed+Cisplatin | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine+Carboplatin, Gemcitabine+Cisplatin
C: Arm Label: Pembrolizumab + Chemotherapy Combo; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Paclitaxel, Drug: Nab-paclitaxel, Drug: Carboplatin | Arm Label: Placebo + Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Nab-paclitaxel, Drug: Carboplatin, Drug: Saline placebo for pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Nab-paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Saline placebo for pembrolizumab; Assigned to Arm(s): Placebo + Chemotherapy
D: Arm Label: MEDI4736; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Other: PLACEBO | Intervention Type: DRUG; Name: MEDI4736; Assigned to Arm(s): MEDI4736 | Intervention Type: OTHER; Name: PLACEBO; Assigned to Arm(s): PLACEBO

Answer: B